1-4 of 4
Greg Rossi
Close
Sort by
Journal Articles

Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin alfa Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia.

Kerry Taylor, MD, Peter Ganly, MD, Veena Charu, MD, Joseph DiBenedetto, MD, Karolyn Kracht, PhD, Greg Rossi, PhD, Enrique Hernandez, MD
Journal: Blood
Blood (2005) 106 (11): 3556.
https://doi.org/10.1182/blood.V106.11.3556.3556
Published: 2005
Journal Articles

Effectiveness of Darbepoetin alfa Administered Every 3 Weeks on Clinical Outcomes in Patients with Hematologic Malignancies and Chemotherapy-Induced Anemia.

Ralph Vincent Boccia, Peter T. Silberstein, Simon Tchekmedyian, Dianne Tomita, Greg Rossi, Greg Otterson
Journal: Blood
Blood (2005) 106 (11): 3767.
https://doi.org/10.1182/blood.V106.11.3767.3767
Published: 2005
Journal Articles

An Evaluation of the Effectiveness of Darbepoetin alfa 300 mcg Every 3 Weeks (Q3W) on Clinical Outcomesin Cancer Patients with Chemotherapy-Induced Anemia.

Ralph Vincent Boccia, Delong Liu, Peter Silberstein, Simon Tchekmedyian, Dianne Tomita, Greg Rossi, Greg Otterson
Journal: Blood
Blood (2004) 104 (11): 5310.
https://doi.org/10.1182/blood.V104.11.5310.5310
Published: 2004
Journal Articles

Efficacy of Darbepoetin Alfa in the Treatment of Chemotherapy-Induced Anemia in Non-Hodgkin’s Lymphoma.

Stephanie A. Gregory, MD, Douglas W. Blayney, MD, Saroj Vadhan-Raj, MD, Dianne K. Tomita, MPH, Greg Rossi, PhD, Barry Mirtsching, MD
Journal: Blood
Blood (2004) 104 (11): 3296.
https://doi.org/10.1182/blood.V104.11.3296.3296
Published: 2004